VIDEO: Rocatinlimab shows long-term effects on atopic dermatitis

In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor rocatinlimab from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.

Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed phase 2 data into the drug that showed “long-lasting effects” on atopic dermatitis.

“A couple of the analyses that we’re seeing here showed that indeed, individuals who were doing well on the drug had reduction in IgE concentrations, reduction in their symptoms and signs of disease, mirroring what we should expect for a systemic therapy,” Chovatiya said.